menu search

GENFF / Genflow Biosciences primed and ready for phase I/II trial after regulatory sign-off

Genflow Biosciences primed and ready for phase I/II trial after regulatory sign-off
Genflow Biosciences PLC (LSE:GENF, OTC:GENFF) said it has received encouraging advice from Belgium's Federal Agency for Medicines and Health Products (FAHMP) which will allow it to start first in human trials on its drug candidate, GF-1002. The trials will focus on patients with Non-Alcoholic Steatohepatitis (NASH), a liver disease that can lead to cirrhosis or liver cancer, rather than healthy volunteers. Read More
Posted: Sep 20 2023, 03:24
Author Name: Proactive Investors
Views: 092091

GENFF News  

Genflow Biosciences well-funded for next R&D milestones

By Proactive Investors
September 28, 2023

Genflow Biosciences well-funded for next R&D milestones

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) said it is funded until at least March 2025 as it summarised the significant progress it has made in t more_horizontal

Genflow Biosciences primed and ready for phase I/II trial after regulatory sign-off

By Proactive Investors
September 20, 2023

Genflow Biosciences primed and ready for phase I/II trial after regulatory sign-off

Genflow Biosciences PLC (LSE:GENF, OTC:GENFF) said it has received encouraging advice from Belgium's Federal Agency for Medicines and Health Products more_horizontal

Genflow Biosciences CEO Reveals the Secrets of Longevity: An Exclusive Interview with Dr Eric Leire

By Proactive Investors
September 19, 2023

Genflow Biosciences CEO Reveals the Secrets of Longevity: An Exclusive Interview with Dr Eric Leire

In conversation with Dr Eric Leire, chief executive of Genflow Biosciences, we delve into the company's groundbreaking work in the field of longevity. more_horizontal


Search within

Pages Search Results: